Of India’s 1.2 billion population, 43.6% speak Hindi as a first language. That’s just over 500 million people. And these 500 million people—close to double of the American population, mind you—have almost no access to credible healthcare information online. At least not in the language they’d rather be reading in.

The problem doesn’t end there. The little information that is available in Hindi is often unreliable, if not downright misleading. A Google Hindi search page, for instance, throws up fruit as a cure for cancer. 


So, in late 2016, five people put their heads together to offer a little something to counter this massive problem. An online health content portal in Hindi to provide accurate medical information on diseases, treatments, medicines, and wellness—myUpchar (my treatment). In six months, the website was attracting a million views a month; and after a whole year, it was the most-viewed health website in India, the company claims. Over 90% of its traffic came from Hindi-speaking small cities, towns and villages in northern India. 

Today, its pageviews stand at 12 million. That’s right behind competitors Delhi-based 1mg and Bengaluru-based Practo’s 19 million and 18 million pageviews, respectively, last month.

Risk of search

According to Similar Web, 84% of the traffic on myUpchar comes via search engines with remaining as direct traffic. When Google changed the search engine matrix in Jan 2019, its traffic dropped from around 10 million visits a month to about 3 million by June

“There was no secret ingredient,” says one of myUpchar’s two co-founders, Manuj Garg. “We shared information in response to questions people asked on our Facebook page.” Basic questions. ‘What is the ideal duration of menstrual cycle?’ ‘How to treat knee pain?’ 

“Initially, most of them were women asking us how to delay their periods for reasons like a college event or a wedding in the family,” says Garg. When it came to answering questions on serious diseases such as dengue or cancer, Garg would consult with doctors.

But it’s not all smooth sailing.

myUpchar was supposed to be India’s answer to WebMD—a US-based health content website, which was acquired by private equity firm KKR for $2.8 billion in 2017. That dream is a long way away.

WebMD is one of the highest-viewed health platforms globally (see chart), with a strategy of earning revenue from advertising and sponsored content. But, in India, pharma companies are barred from advertising to the public. And this is where myUpchar jumped in with both feet. And without a business model.

Meanwhile, competition has sniffed an opportunity.


Ruhi Kandhari

Ruhi writes on the impact of healthcare policies, trends in the healthcare sector and developments on the implementation of Electronic Health Records in India. She has an M. Sc. in Development Studies from the London School of Economics.

View Full Profile

Available exclusively to subscribers of The Ken India

This story is a part of The Ken India edition. Subscribe. Questions?


Annual Subscription

12-month access to 200+ stories, archive of 800+ stories from our India edition. Plus our premium newsletters, Beyond The First Order and The Nutgraf worth Rs. 99/month or $2/month each for free.

Rs. 2,750


Quarterly Subscription

3-month access to 60+ new stories with 3-months worth of archives from our India edition. Plus our premium newsletters, Beyond The First Order and The Nutgraf worth Rs. 99/month or $2/month each for free.

Rs. 1,750


Single Story

Instant access to this story for a year along with comment privileges.

Rs. 500


Annual Subscription

12-month access to 150+ stories from Southeast Asia.

$ 120


Quarterly Subscription

3-month access to 35+ stories from Southeast Asia.

$ 50


Single Story

Instant access to this story for a year along with comment privileges.

$ 20



What is The Ken?

The Ken is a subscription-only business journalism website and app that provides coverage across two editions - India and Southeast Asia.

What kind of stories do you write?

We publish sharp, original and reported stories on technology, business and healthcare. Our stories are forward-looking, analytical and directional — supported by data, visualisations and infographics.

We use language and narrative that is accessible to even lay readers. And we optimise for quality over quantity, every single time.

What do I get if I subscribe?

For subscribers of the India edition, we publish a new story every weekday, a premium daily newsletter, Beyond The First Order and a weekly newsletter - The Nutgraf.

For subscribers of the Southeast Asia edition, we publish a new story three days a week and a weekly newsletter, Strait Up.

The annual subscription will get you complete, exclusive access to our archive of previously published stories for your edition, along with access to our subscriber-only mobile apps, our premium comment sections, our newsletter archives and several other gifts and benefits.

Do I need to pay separately for your premium newsletters?

Nope. Paid, premium subscribers of The Ken get our newsletters delivered for free.

Does a subscription to the India edition grant me access to Southeast Asia stories? Or vice-versa?

Afraid not. Each edition is separate with its own subscription plan. The India edition publishes stories focused on India. The Southeast Asia edition is focused on Southeast Asia. We may occasionally cross-publish stories from one edition to the other.

Do you offer an all-access joint subscription for both editions?

Not yet. If you’d like to access both editions, you’ll have to purchase two subscriptions separately - one for India and the other for Southeast Asia.

Do you offer any discounts?

No. We have a zero discounts policy.

Is there a free trial I can opt for?

We don’t offer any trials, but you can sign up for a free account which will give you access to the weekly free story, our archive of free stories and summaries of the paid stories. You can stay on the free account as long as you’d like.

Do you offer refunds?

We allow you to sample our journalism for free before signing up, and after you do, we stand by its quality. But we do not offer refunds.

I am facing some trouble purchasing a subscription. What can I do?

Please write to us at [email protected] detailing the error or queries.